ESMO GI 2026

LEXINGTON, Mass., July 6, 2026 Agenus announced new three-year follow-up results from the fully enrolled Phase 1b C-800-01 study...

LONDON, Boston & Budapest, July 2, 2026 Treos Bio announced new translational findings from its Phase Ib/II OBERTO-301 clinical...

REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...

SHANGHAI, China, July 2, 2026 Multitude Therapeutics Co., Ltd. announced encouraging interim Phase I clinical results for its CDH17-directed...